Several analysts have recently updated their ratings and price targets for Hims & Hers Health (NYSE: HIMS):
- 8/21/2026 – Hims & Hers Health had its price target lowered by Barclays PLC from $39.00 to $35.00. They now have an “overweight” rating on the stock.
- 8/15/2026 – Hims & Hers Health was upgraded by Wall Street Zen from “sell” to “hold”.
- 8/11/2026 – Hims & Hers Health had its price target raised by Deutsche Bank Aktiengesellschaft from $25.00 to $26.00. They now have a “hold” rating on the stock.
- 8/11/2026 – Hims & Hers Health had its price target raised by TD Cowen from $25.00 to $30.00. They now have a “hold” rating on the stock.
- 8/11/2026 – Hims & Hers Health had its price target raised by Morgan Stanley from $21.00 to $28.00. They now have an “equal weight” rating on the stock.
- 8/11/2026 – Hims & Hers Health had its price target lowered by Citigroup Inc. from $35.00 to $33.00. They now have a “neutral” rating on the stock.
- 8/11/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $30.00 to $32.00. They now have a “neutral” rating on the stock.
- 8/11/2026 – Hims & Hers Health had its price target raised by Needham & Company LLC from $35.00 to $42.00. They now have a “buy” rating on the stock.
- 8/7/2026 – Hims & Hers Health had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 7/24/2026 – Hims & Hers Health had its price target raised by Truist Financial Corporation from $23.00 to $27.00. They now have a “hold” rating on the stock.
- 7/23/2026 – Hims & Hers Health had its price target raised by Citigroup Inc. from $28.00 to $35.00. They now have a “neutral” rating on the stock.
- 7/13/2026 – Hims & Hers Health was upgraded by Zacks Research from “strong sell” to “hold”.
- 7/9/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $36.00 to $37.00. They now have a “neutral” rating on the stock.
- 7/1/2026 – Hims & Hers Health had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $40.00. They now have a “buy” rating on the stock.
- 7/1/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $25.00 to $36.00. They now have a “neutral” rating on the stock.
Insider Transactions at Hims & Hers Health
In related news, CFO Oluyemi Okupe sold 4,938 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $29.99, for a total value of $148,090.62. Following the sale, the chief financial officer directly owned 264,117 shares in the company, valued at approximately $7,920,868.83. The trade was a 1.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the transaction, the insider directly owned 48,961 shares in the company, valued at $1,363,563.85. The trade was a 25.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,769 shares of company stock worth $6,035,648 in the last 90 days. Insiders own 11.76% of the company’s stock.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Hims & Hers Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.
